Abstract:The FDA publishes 2 lists of approved drugs. The lists are known popularly as the "Purple Book" and the "Orange Book." The Purple Book lists biological drugs, also known as "biologics" or "large-molecule drugs," while the Orange Book lists small-molecule drugs. Both books are also supposed to identify the patents protecting each listed drug, so that prospective manufacturers of less-expensive copies of the drugs—called "biosimilars" for large-molecule drugs and "generics" for small-molecule drugs—can assess their infringement risk and prepare for entry. In practice, however, the Purple Book provides far less disclosure about patents than the Orange Book. Without knowing what patents are looming, the prospective biosimilar manufacturer must make investment and manufacturing decisions in the dark. That darkness discourages biosimilar entry, reduces competition, and leaves patients and insurers to pay for brand drugs at unnecessarily high prices. Such a result is ironic because price reduction was a key goal of the Biologics Price Competition and Innovation Act—also known as the "Biosimilars Act" [1]. Congress passed the Act in 2010 to create an abbreviated pathway for biosimilar entry, just as the Hatch-Waxman Act in 1984 created an abbreviated pathway for generic entry [2].

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act